This program is available until December 31, 2020.
Program Chair: Randall Velliquette, SBB(ASCP) Speakers: Sunitha Vege; Craig Tauscher; Julie Kirkegaard, MT(ASCP)SBB; Anna Burgos, MT(ASCP)SBB; Christine Lomas-Francis, MSc, FIBMS; Hallie Lee-Stroka, MT(ASCP)SBB; Regina Leger, MSQA,MT(ASCP)SBB, CMQ/OE(ASQ); Sandra Nance, MS, MT(ASCP)SBB; Paul Mansfield, MT(ASCP), SBB; Sue Johnson, MSTM, MT(ASCP)SBB; Dolores Figueroa, MT(ASCP)SBB; Kelly Winkhart, SBB(ASCP)CM; Donna Mirabella, MS,MT(ASCP)SBB Intended Audience: Technologist, Supervisor, Student (MD, MT, SBB), Residents/Fellow, Physician, Medical Director, Manager, Director Teaching Level: Intermediate
Utilize roundtable group discussions to learn how peers approach and solve antibody identification problems and how they currently use DNA testing.
Discover how the combined use of serology and DNA testing methods can be used to solve difficult cases and why the results of serology and DNA testing might appear discrepant.
Describe the use of advanced serological techniques, including enzymes and chemicals, as tools for antibody identification and discuss the importance of the use of multiple methods, including DNA testing, for resolving complex cases.
Description: Join colleagues from near and far for stimulating discussions and enjoy solving immunohematology problem cases. Using a roundtable discussion format, this program will present moderate to complex immunohematology case studies introduced by speakers and then discussed with participants with guidance from team leaders. Utilizing a small group format, participants will be given the opportunity to discuss cases and expand their problem solving skills. An introduction to DNA-based testing methods available in the current Immunohematology Laboratory environment and case presentations involving DNA-based testing will begin the program. Presentations of case studies applying routine serological methods will follow in the second portion of the session. The case studies will evolve in complexity by incorporating advanced serological techniques and approaches to recognize and handle monoclonal antibody drug interference.
Please note: Paul Mansfield and Sandra Nance did not consent to presentation capturing and being recorded; therefore, their presentations are not included in the on-demand presentation.